reports
- Julian Dobrovolschi
- Anis Zgaya
- Bruno Cavalier
- Louis Boujard
- CFA
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
EL ESSILORLUXOTTICA SA
BRBY BURBERRY GROUP PLC
VIRP VIRBAC SA
RBT ROBERTET SA
KER KERING SA
ELIS ELIS SA
01913 PRADA S.P.A.
MONC MONCLER SPA
ONTEX ONTEX GROUP N.V.
BCHN BURCKHARDT COMPRESSION HOLDING AG
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
GRP GREENCOAT RENEWABLES
SFQ SAF-HOLLAND SE
FLOW FLOW TRADERS LTD
- Anis Zgaya
- Bruno Cavalier
- Louis Boujard
- CFA
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
EL ESSILORLUXOTTICA SA
BRBY BURBERRY GROUP PLC
VIRP VIRBAC SA
RBT ROBERTET SA
KER KERING SA
ELIS ELIS SA
01913 PRADA S.P.A.
MONC MONCLER SPA
ONTEX ONTEX GROUP N.V.
BCHN BURCKHARDT COMPRESSION HOLDING AG
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
GRP GREENCOAT RENEWABLES
SFQ SAF-HOLLAND SE
FLOW FLOW TRADERS LTD
- ING Helpdesk
Benelux Morning Notes
Azelis: Highlights ING Benelux Conference London. Barco: Highlights ING Benelux Conference London. Kinepolis: Highlights ING Benelux Conference London. Melexis: Highlights ING Benelux Conference London. ABN AMRO: Dutch State reducing stake to 20%. ASML: x Mistral, a bet on A.I.. Kinepolis: Cineplex August 2025 box office revenue at 87% of 2019 level, down 27% YoY
Disclosure of notification received from Mawer
Disclosure of notification received from Mawer Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 5 September 2025 – 5:40 PM CET Disclosure of notification received from Mawer Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies, Fagron received a notification from Mawer. Notification by Mawer Investment Management Ltd On 3 September 2025, Fagron received a notification that the shareholding of Mawer Investment Management Ltd, crossed the disclosure threshold of 5% downwards on 29 August 2025 as the result of t...
Openbaarmaking van kennisgeving ontvangen van Mawer
Openbaarmaking van kennisgeving ontvangen van Mawer Gereglementeerde informatie Nazareth (België)/Rotterdam (Nederland), 5 september 2025 – 17u40 CET Openbaarmaking van kennisgeving ontvangen van Mawer Fagron heeft een kennisgeving ontvangen op grond van de Belgische Wet van 2 mei 2007 op de openbaarmaking van belangrijke deelnemingen in beursgenoteerde vennootschappen van Mawer. Kennisgeving van Mawer Investment Management Ltd Op 3 september 2025 ontving Fagron een melding dat het belang van Mawer Investment Management Ltd de meldingsdrempel van 5% had overschreden op 29 augustus 2025...
Aegon successfully sells 12.5 million shares in a.s.r.
Aegon successfully sells 12.5 million shares in a.s.r. NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, SOUTH AFRICA, JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW. This press release is for information purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities and the offer of a.s.r. shares does not constitute a public offering other than to qualified investors in any jurisdiction. Schiphol, Septembe...
Crescent NV: 1 director
A director at Crescent NV bought 134,160,256 shares at 0.007EUR and the significance rating of the trade was 77/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
Aegon to sell approximately 12.5 million shares in a.s.r. via an accel...
Aegon to sell approximately 12.5 million shares in a.s.r. via an accelerated placing NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, SOUTH AFRICA, JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW. This press release is for information purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities and the offer of a.s.r. shares does not constitute a public offering other than to qualified investors in any ju...
- ING Helpdesk
- Jacob Mekhael
- Livio Luyten
- Thomas Couvreur
- ING Helpdesk
REVISED VERSION - Benelux Morning Notes - updated to include IBA news
CFE: 1H results a bit light, FY outlook maintained. CMB.TECH: VLCC reasonable, pressure on Dry Bulk rates. dsm-firmenich: Givaudan CMD; Strategy 2030. Gimv: Investing in specialised healthcare services in the Netherlands. IBA: More sales but at lower margin
Aegon implements increase in share buyback program
Aegon implements increase in share buyback program Schiphol, August 25, 2025 - Aegon today announces that the EUR 200 million share buyback program that began on July 1, 2025, has been increased by EUR 200 million to EUR 400 million with effect as of today. This increase was first announced on , 2025. To date, share repurchases for an aggregate purchase price of EUR 87 million have been completed, representing approximately 43% completion of the initial EUR 200 million program. The increased share buyback is expected to be completed by December 15, 2025, barring unforeseen circumstances. A...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Wim Lewi
- ING Helpdesk
Benelux Morning Notes
AEGON: Addition of €200m to existing SBB, considering US domicile, results mixed. Alfen: 19% EBITDA cut, mid-point new 2026 guidance. Flow Traders: Positive volumes, negative volatility. Kinepolis: Strong profit beat on better operating leverage, higher ticket and ITS per visitor. Recticel: Peer Rockwool 2Q25 results. Tessenderlo: Solid 1H25 beat, guidance maintained. VGP: Strong results, more news on JVs to come
Aegon reports first half year 2025 results
Aegon reports first half year 2025 results Schiphol, August 21, 2025 - Please click to access all 1H 2025 results related documents. 1H 2025 Financial highlights Net profit of EUR 606 million compared with a net loss of EUR 65 million for the first half of 2024Operating result of EUR 845 million, up 19% compared with the first half of 2024, reflecting business growth and improved experience variance in the United States Valuation equity – the sum of shareholders’ equity and the contractual service margin (CSM) after estimated tax adjustment – per share of EUR 8.47; a reduction of 5% i...
Galapagos Creates New Subscription Right Plan
Galapagos Creates New Subscription Right Plan Mechelen, Belgium; August 7, 2025, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 1,800,000 subscription rights under a new subscription right plan. On August 7, 2025, the Board of Directors of Galapagos approved “Subscription Right Plan 2025 (B)”, intended for personnel of the Company and its subsidiaries, within the framework of the authorized capital. Under this subscription right plan, 1,800,000 subscription rights were created, subject to acceptance, for senior...
Galapagos creëert nieuw inschrijvingsrechtenplan
Galapagos creëert nieuw inschrijvingsrechtenplan Mechelen, België; 7 augustus 2025, 22.01 CET; gereglementeerde informatie – Galapagos NV (Euronext & NASDAQ: GLPG) kondigt vandaag aan dat haar Raad van Bestuur 1.800.000 inschrijvingsrechten heeft gecreëerd onder een nieuw inschrijvingsrechtenplan. De Raad van Bestuur van Galapagos heeft op 7 augustus 2025 “Inschrijvingsrechtenplan 2025 (B)”, bestemd voor leden van het personeel van de Vennootschap en van haar dochtervennootschappen, goedgekeurd binnen het kader van het toegestaan kapitaal. Onder dit inschrijvingsrechtenplan werden 1.80...
- Jacob Mekhael
Galapagos Receives FDA RMAT designation for GLPG5101 in r/r MCL
Galapagos announced that the FDA has granted RMAT designation to GLPG5101 (CD19- CAR-T) to treat relapsed/refractory mantle cell lymphoma (r/r MCL). This is based on the strong data that GLPG5101 has demonstrated in the MCL cohort in the phase 1/2 (ATLANTA-1) trial in r/r NHL, and comes with a number of potential benefits including eligibility for accelerated approval, and could further support external discussions as Galapagos explores strategic alternatives for the cell therapy business. Accum...
- Jacob Mekhael
- Lynn Hautekeete
- Mathijs Geerts Danau
- Michiel Declercq
- Thomas Couvreur
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.